All In Biotech

Drug Trial Radar · NCT02862535

Study to Evaluate the Safety and Tolerability of Andecaliximab as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Participants With Gastric or Gastroesophageal Junction Adenocarcinoma

A Phase 1b Study to Evaluate the Safety and Tolerability of Andecaliximab (GS-5745) as Monotherapy and in Combination With Anti-Cancer Agents in Japanese Subjects With Gastric or Gastroesophageal Junction Adenocarcinoma

Last checked: Nov 20, 2026Latest source record: Dec 24, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registry

Status

Terminated

Enrollment

36

Actual

Start

Sep 20, 2016

Primary completion

Oct 25, 2019

Study completion Oct 25, 2019

Sponsor

Lead sponsor
Gilead SciencesGilead Sciences (GILD)
Sponsor type
Industry
First posted
Aug 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 20 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of this study is to characterize the safety and tolerability of andecaliximab as monotherapy and in combination with anti-cancer agents in Japanese participants with inoperable advanced or recurrent gastric or recurrent gastroesophageal junction (GEJ) adenocarcinoma.

Conditions

  • Gastric Adenocarcinoma

Interventions

  • AndecaliximabDrug

    Administered via intravenous (IV) infusion (approximately 30 minutes)

  • S-1Drug

    Administered orally

  • CisplatinDrug

    Administered via IV infusion on Day 8 of every 5 weeks

  • OxaliplatinDrug

    Administered via IV infusion for over 2 hours on Day 1 of each 21-day cycle

  • NivolumabDrug

    Administered via IV infusion (approximately 60 minutes) every 2 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percentage of Participants Experiencing Treatment-Emergent Adverse Events (TEAEs)Time frame: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)
  2. Percentage of Participants Experiencing Treatment-Emergent Laboratory AbnormalitiesTime frame: First dose date up to 82.4 weeks plus 30 days (or if applicable, up to 5 months after permanent withdrawal of nivolumab)

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Site not named

    Nagoya, Japan

  • Site not named

    Osaka, Japan

  • Site not named

    Tokyo, Japan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.